^(13)C-美沙西汀呼气试验评价肝硬化患者肝细胞储备功能的临床价值

Clinical Value of ^(13)C-Methacetin Breath Test in Evaluation of Hepatic Function of Patients with Liver Cirrhosis

目的:探讨肝硬化患者13C-美沙西汀肝功能呼气试验检测的特点,比较13C-美沙西丁呼气试验与临床Ch ild-Pugh分级方法差异。方法:肝硬化患者34例和正常人20例进行13C-美沙西汀呼气试验。口服13C-美沙西丁50 m g,收集检测并比较研究对象服药前、服药后10、20、30、40、50、60、80、100、120 m in等10个时间段呼出气体中13CO2丰度(DOB)、代谢速率(M V)以及累积丰度(CD)等。结果:34例肝硬化患者13C-美沙西丁呼气试验肝功能分级与临床Ch ild-Pugh分级间无明显差异。结论:13C-美沙西丁呼气试验检测能准确、直观地反映肝硬化患者肝功能状况。

Objective：To investigate the characteristics of the ^13C-Methacetin breath test （^13C-MBT） as a tool to monitor hepatic function of patients with liver cirrhosis,to compare the difference of ^13C-MBT with clinical Child-Pugh class. Methods： Thirty-four patients with liver cirrhosis and twenty healthy controls underwent 13 C-MBT. ^13 C- methacetin （50 rag） was given orally,and the levels of ^13CO2 delta over baseline （DOB）,metabolisation velocity （MV） and cumulative percentage doses （CD） before and 10,20,30,40,50,60,80,100 and 120 min after was determined and compared, by non-dispersive infrared spectrometry. Results：There was hardly any difference between ^13C-MBT and clinical Child-Pugh class of thirty-four patients with liver cirrhosis. Conclusion ：The severity of liver damage can he directly and effectively evaluated by ^13C-MBT in patients with cirrhosis.